FDA Approves Binosto for Osteoporosis

BINOSTO (alendronate sodium) 70mg effervescent tablet for oral solution by Mission Pharmacal
BINOSTO (alendronate sodium) 70mg effervescent tablet for oral solution by Mission Pharmacal
EffRx announced that the FDA has approved Binosto (alendronate sodium) Effervescent Tablets for the treatment of osteoporosis in postmenopausal women, and to increase bone mass in men with osteoporosis. Binosto is a once-weekly, strawberry-flavored effervescent tablet containing alendronate 70mg. These effervescent tablets rapidly dissolve in water to make a buffered solution. Binosto is the first effervescent osteoporosis treatment alternative to tablets.

Binosto, a bisphosphonate, is a specific inhibitor of osteoclast-mediated bone resorption. It acts as a chelator of calcium and has a high binding affinity for mineralized bone.
 
Binosto will be available in packs of 4 and 12 tablets sometime in the third quarter of 2012.

For more information visit www.effrx.com.